Oncologists’ Perceptions of Tumor Genomic Profiling and Barriers to Communicating Secondary Hereditary Risks to African American Cancer Patients

Author:

Hall Michael J1,D’Avanzo Paul A2,Chertock Yana1,Kelly Patrick JA2,Brajuha Jesse2,Singley Katie2,Luck Caseem2,Bass Sarah Bauerle2

Affiliation:

1. ¹Fox Chase Cancer Center

2. ²Temple University

Abstract

Abstract Background Tumor genomic profiling (TGP) identifies targets for precision cancer treatments, but also secondary hereditary risks. Oncologists are poorly trained to communicate these results, especially among patients with lower health literacy, poorer genetics knowledge, and higher mistrust. African American (AA) patients are especially vulnerable due to significant cancer disparities and lower uptake of TGP.Methods This mixed-methods study used semi-structured interviews of oncologists to inform development of an online survey with a convenience sample of US-based oncologists (n = 50) to assess perceptions of the challenges of TGP and communicating results to AA patients.Results Most interviewed oncologists felt it was important to consider racial/cultural differences when communicating about hereditary risks. Cost, family dynamics, discrimination concerns, and medical mistrust were identified as particularly salient. Survey respondents’ views related to AAs and perceptions of TGP were strongly associated with years since completing training, with recent graduates expressing stronger agreement with statements identifying barriers/disadvantages to TGP for AA patients.Conclusions Oncologists who had more recently completed training expressed more negative perceptions of TGP and more perceived challenges in communicating about TGP with their AA patients. Focused training for oncologists that address barriers specific to AAs may be helpful in supporting improved communication about TGP.

Publisher

Research Square Platform LLC

Reference51 articles.

1. Molecular profiling for precision cancer therapies;Malone ER;Genome Med,2020

2. Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area;Horgan D;Healthc (Basel),2023

3. de Moor JS, et al. Oncologist Confidence in Genomic Testing and Implications for Using Multimarker Tumor Panel Tests in Practice. JCO Precis Oncol; 2020. p. 4.

4. Freedman AN, et al. Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States. Volume 2. JCO Precis Oncol; 2018.

5. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life;Morganti S;Crit Rev Oncol Hematol,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3